A preliminary study on the joint parameter Lym% and HGB for the prediction of severe and nonsevere COVID-19
The aim of this study was to identify the parameters in routine blood tests that can be used to evaluate the severity of coronavirus disease 2019 (COVID-19) and thus assist in clinically predicting the extent of progression.
This study retrospectively analyzed the epidemiological, clinical symptom and laboratory examination data of 159 COVID-19 patients. The percentage of lymphocytes (Lym%) and hemoglobin (HGB) were integrated into a joint parameter, Lym%&HGB, by binary logistic regression.
Both Lym% and HGB gradually decreased with disease progression whereas the joint parameter Lym%&HGB increased gradually with disease progression. When using Lym%, HGB, and Lym%&HGB to predict COVID-19 severity, the area under the receiver operating characteristic (ROC) curve (AUC) was 0.89, 0.79, and 0.92, respectively. The dynamic change curves showed that Lym% and HGB continued to decline while Lym%&HGB continued to increase with disease progression in patients with severe COVID. The change in Lym%&HGB was more prominent than the changes in Lym% and HBG.
The joint parameter Lym%&HGB can serve as a good tool to differentiate severe and nonsevere COVID-19, and it has a higher sensitivity and specificity than either Lym% or HGB alone.
Figure 1
Figure 2
Figure 3
Posted 12 Jun, 2020
A preliminary study on the joint parameter Lym% and HGB for the prediction of severe and nonsevere COVID-19
Posted 12 Jun, 2020
The aim of this study was to identify the parameters in routine blood tests that can be used to evaluate the severity of coronavirus disease 2019 (COVID-19) and thus assist in clinically predicting the extent of progression.
This study retrospectively analyzed the epidemiological, clinical symptom and laboratory examination data of 159 COVID-19 patients. The percentage of lymphocytes (Lym%) and hemoglobin (HGB) were integrated into a joint parameter, Lym%&HGB, by binary logistic regression.
Both Lym% and HGB gradually decreased with disease progression whereas the joint parameter Lym%&HGB increased gradually with disease progression. When using Lym%, HGB, and Lym%&HGB to predict COVID-19 severity, the area under the receiver operating characteristic (ROC) curve (AUC) was 0.89, 0.79, and 0.92, respectively. The dynamic change curves showed that Lym% and HGB continued to decline while Lym%&HGB continued to increase with disease progression in patients with severe COVID. The change in Lym%&HGB was more prominent than the changes in Lym% and HBG.
The joint parameter Lym%&HGB can serve as a good tool to differentiate severe and nonsevere COVID-19, and it has a higher sensitivity and specificity than either Lym% or HGB alone.
Figure 1
Figure 2
Figure 3